Kymera
potent degrader and best in class stabilizer benefits of degradation | Kymera
Company
Deck Type
Sector
Industry
Deck date
December 2023
Slide
34 of 46
Similar slides by Kymera
See diffirences between slides (animation)
Investor Presentation
November 2023
potent degrader and best in class stabilizer benefits of degradation | Kymera
Investor Presentation
August 2023
degraders in oncology | Kymera
Investor Presentation
June 2023
degraders in oncology | Kymera
Investor Day
December 2021
is the that modulates the tumor suppressor | Kymera
Related slides by other companies
AstraZeneca
Results
November 2024
oncology highlights continuing momentum across oncology with data at key medical congresses in and expanding into bladder cancer and advancing next gen and advancing with upcoming data at ash only regimen to show benefit potential new soc patients amplify fixed duration in clinically meaningful improvement trend to benefit ineligible phase next wave in house novel high rate in high levels of complete remission in good tolerability | AstraZeneca
MindMed
Investor Presentation
June 2023
preclinical data indicate potential enhanced benefit risk profile | MindMed
argenx SE
Investor Presentation
March 2023
strengthened data story to clear clinical benefit broadened safety immunology | argenx SE
AvePoint
Investor Presentation
November 2021
why we win depth and breadth of platform approach benefits a | AvePoint
Other recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Results
December 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights